Search Result

Results for "

gasdermin+d

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AIM2 (1) Aldehyde Dehydrogenase (ALDH) (2) Apoptosis (3) Autophagy (1) Caspase (7) Cuproptosis (2) Deubiquitinase (1) Heme Oxygenase (HO) (4) IKK (1) Integrin (1) Interleukin Related (7) Isotope-Labeled Compounds (1) Keap1-Nrf2 (4) Lactate Dehydrogenase (1) Mixed Lineage Kinase (4) MOFs (1) Necroptosis (4) NF-κB (1) NO Synthase (4) NOD-like Receptor (NLR) (8) P2Y Receptor (1) Pyroptosis (12) Reference Standards (2) TNF Receptor (4)
By Research Areas:	Cancer (4) Cardiovascular Disease (5) Endocrinology (4) Inflammation/Immunology (12) Metabolic Disease (6) Neurological Disease (4)

By Targets:

AIM2 (1)

Aldehyde Dehydrogenase (ALDH) (2)

Apoptosis (3)

Autophagy (1)

Caspase (7)

Cuproptosis (2)

Deubiquitinase (1)

Heme Oxygenase (HO) (4)

IKK (1)

Integrin (1)

Interleukin Related (7)

Isotope-Labeled Compounds (1)

Keap1-Nrf2 (4)

Lactate Dehydrogenase (1)

Mixed Lineage Kinase (4)

MOFs (1)

Necroptosis (4)

NF-κB (1)

NO Synthase (4)

NOD-like Receptor (NLR) (8)

P2Y Receptor (1)

Pyroptosis (12)

Reference Standards (2)

TNF Receptor (4)

By Research Areas:

Cancer (4)

Cardiovascular Disease (5)

Endocrinology (4)

Inflammation/Immunology (12)

Metabolic Disease (6)

Neurological Disease (4)

Inhibitors & Agonists

Screening-Bibliotheken

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Art. -Nr.	Produktname	Target	Forschungsgebiete	Chemical Structure

HY-B0240

Disulfiram 140+ Cited Publications Tetraethylthiuram disulfide; TETD	Aldehyde Dehydrogenase (ALDH) Interleukin Related Pyroptosis Apoptosis Cuproptosis	Metabolic Disease Cancer
Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Disulfiram, a copper ion carrier, with Cu ²⁺ increases intracellular ROS levels and induces cuproptosis .

HY-13453

BAY 11-7082 Maximum Cited Publications 450 Publications Verification BAY 11-7821	IKK Deubiquitinase Autophagy Apoptosis NF-κB	Inflammation/Immunology Cancer
BAY 11-7082 is an IκBα phosphorylation and NF-κB inhibitor. BAY 11-7082 selectively and irreversibly inhibits the TNF-α-induced phosphorylation of IκB-α, and decreases NF-κB and expression of adhesion molecules. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 (IC₅₀=0.19, 0.96 μM, respectively). BAY 11-7082 inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells .

HY-100573

Necrosulfonamide 135+ Cited Publications	Mixed Lineage Kinase Necroptosis Pyroptosis Caspase NOD-like Receptor (NLR) Keap1-Nrf2 TNF Receptor Interleukin Related NO Synthase Heme Oxygenase (HO)	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways .

HY-111674

LDC7559 20+ Cited Publications	Pyroptosis	Inflammation/Immunology
LDC7559 is a gasdermin D (GSDMD) inhibitor via blocking neutrophil extracellular trap (NET) in the late stages .

HY-W075517

ZIF-8 2-Methylimidazole zinc salt	MOFs Caspase Pyroptosis	Cancer
ZIF-8 (2-Methylimidazole zinc salt) is a pyroptosis inducer that activates the caspase-1/gasdermin D-dependent pyroptosis pathway. ZIF-8 induces pyroptotic cell death accompanied by necrosis and immunogenic cell death. ZIF-8 initiates in situ immunity, activates anti-tumor immunity, and reprograms the immunosuppressive tumor microenvironment to inhibit tumor growth. ZIF-8 acts as a pH-responsive and stimulus-responsive drug release inducer. ZIF-8 is applicable to cancer-related research .

HY-111675

Ac-FLTD-CMK 5+ Cited Publications	Caspase Pyroptosis	Inflammation/Immunology
Ac-FLTD-CMK, a gasdermin D (GSDMD)-derived inhibitor, is a specific inflammatory caspases inhibitor. Ac-FLTD-CMK is effective against caspases-1 (IC₅₀ of 46.7 nM), caspases-4 (IC₅₀ of 1.49 μM), caspases-5 (IC₅₀ of 329 nM), and caspases-11 , but not the apoptotic caspases such as caspase-3 .

HY-B0240R

Disulfiram (Standard) Tetraethylthiuram disulfide (Standard); TETD (Standard)	Reference Standards Aldehyde Dehydrogenase (ALDH) Interleukin Related Pyroptosis Apoptosis Cuproptosis	Metabolic Disease Cancer
Disulfiram (Standard) is the analytical standard of Disulfiram. This product is intended for research and analytical applications. Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Disulfiram + Cu ²⁺ increases intracellular ROS levels triggering apoptosis of ovarian cancer stem cells ^[1-6].

HY-152670

JC2-11 1 Publications Verification	NOD-like Receptor (NLR) AIM2	Inflammation/Immunology
JC2-11 is an inhibitor of inflammatory corpuscles. JC2-11 inhibits domain-containing protein NLRC 4, absent in melanoma 2 (AIM 2) and non-canonical (NC) inflammatory corpuscles. JC2-11 reduces the secretion of caspase-1 (p20), the cleavage of gasdermin D (GSDMD), and the releases of IL-1β and lactate dehydrogenases (LDH) in inflammatory bodies. JC2-11 inhibits the activation of inflammatory bodies by destroying the production of reactive oxygen species and the activity of caspase-1 .

HY-100573A

(E/Z)-Necrosulfonamide 1 Publications Verification	Mixed Lineage Kinase Necroptosis Pyroptosis Caspase NOD-like Receptor (NLR) Keap1-Nrf2 TNF Receptor Interleukin Related NO Synthase Heme Oxygenase (HO)	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
(E/Z)-Necrosulfonamide is a racemic compound of Necrosulfonamide (HY-100573). Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.

HY-149604

NLRP3-IN-21 1 Publications Verification	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-21 (compound L38) is a NLRP3 inflammasome inhibitor with inflammatory properties. NLRP3-IN-21 inhibits NLRP3 inflammasome activation and pyroptosis by suppressing gasdermin D cleavage, ASC oligomerization, and NLRP3 inflammasome assembly .

HY-161727

P2Y14R antagonist 1	P2Y Receptor NOD-like Receptor (NLR)	Inflammation/Immunology
P2Y14R antagonist 1 (compound I-17) is a selective P2Y14R antagonist with an IC₅₀ of 0.6 nM. It exhibits potent P2Y14R antagonistic activity, both in vitro and in vivo efficacy, and favorable pharmacokinetic profiles. P2Y14R antagonist 1 reduces the release of inflammatory factors and cell pyroptosis through the NOD-like receptor family pyrin domain-containing 3 (NLRP3)/gasdermin D (GSDMD) signaling pathway. P2Y14R antagonist 1 holds promise for research in the field of acute gouty arthritis .

HY-173234

GI-Y2	Pyroptosis Interleukin Related	Cardiovascular Disease
GI-Y2 is an orally active, selective Gasdermin D (GSDMD) inhibitor (K_d = 36.0 μM) with anti-pyroptosis activity. GI-Y2 targets GSDMD, impairs membrane anchoring of GSDMD-NT, and blocks GSDMD‑dependent lipid binding and pore formation. GI-Y2 suppresses GSDMD‑dependent pyroptosis and inflammation, mitigates atherosclerosis and cardiac injury, boosts cell survival, and reduces IL‑1β/IL‑18 secretion. GI-Y2 can be used for the research of atherosclerosis and septic myocardial injury .

HY-100573S

Necrosulfonamide-d4	Isotope-Labeled Compounds Mixed Lineage Kinase Necroptosis Pyroptosis Caspase NOD-like Receptor (NLR) Keap1-Nrf2 TNF Receptor Integrin NO Synthase Heme Oxygenase (HO)	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
Necrosulfonamide-d₄ is the deuterium labeled Necrosulfonamide (HY-100573). Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.

HY-181168

Lb54	Caspase Pyroptosis	Inflammation/Immunology
Lb54 is a caspase-3 and caspase-7 activator with an EC₅₀ of 660.9 nM for human procaspase-3. Lb54 activates caspase-3/7, which cleaves Gasdermin D (GSDMD) at aspartic acid residue 87 to generate a p10 fragment, preventing formation of the pore-forming p30 fragment of GSDMD. Lb54 suppresses GSDMD-mediated pyroptosis through caspase-3/7 activation, thereby attenuating inflammatory responses and conferring protection against sepsis. Lb54 alleviates acute lung injury, and inhibited systemic inflammation by restraining the maturation of monocyte-derived dendritic cells. Lb54 can be used for the research of sepsis .

HY-180830

NLRP3-IN-86	NOD-like Receptor (NLR) Lactate Dehydrogenase Interleukin Related Pyroptosis	Inflammation/Immunology
NLRP3-IN-86 (Compound 8a), a derivative of Songorine (HY-N2080), is a potent and selective NLRP3 inflammasome inhibitor. NLRP3-IN-86 can reduce LPS (HY-D1056)- and Nigericin (HY-127019)-stimulated lactate dehydrogenase (LDH) release (IC₅₀ = 2.69 μM in THP-1 cells and 1.75 μ M in J774A.1 cells). NLRP3-IN-86 can inhibit gasdermin D (GSDMD) cleavage and IL-1β secretion. NLRP3-IN-86 can inhibit cell pyroptosis. NLRP3-IN-86 can be used for research of inflammation .

HY-100573R

Necrosulfonamide (Standard)	Mixed Lineage Kinase Reference Standards Necroptosis Pyroptosis Caspase NOD-like Receptor (NLR) Keap1-Nrf2 TNF Receptor Interleukin Related NO Synthase Heme Oxygenase (HO)	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
Necrosulfonamide (Standard) is the analytical standard of Necrosulfonamide (HY-100573). This product is intended for research and analytical applications. Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways .

Art. -Nr.	Produktname

HY-L059

Pyroptosis Compound Library	1,885 compounds
Programmed cell death pathways, including apoptosis, pyroptosis and necroptosis, are regulated by unique sets of host proteins that coordinate a variety of biological outcomes. Pyroptosis is a highly inflammatory form of programmed cell death that occurs most frequently upon infection with intracellular pathogens and is likely to form part of the antimicrobial response. This process promotes the rapid clearance of various bacterial, viral, fungal and protozoan infections by removing intracellular replication niches and enhancing the host's defensive responses. Pyroptosis has been widely studied in inflammatory and infection disease models. Recently, there are growing evidences that pyroptosis also plays an important role in the development of cancer, cardiovascular diseases and Metabolic disorder, etc. MCE designs a unique collection of 1,885 pyroptosis-related compounds mainly focusing on the key targets in the pyroptosis signaling pathway and can be used in the research of pyroptosis signal pathway and related diseases.

Pyroptosis Compound Library

1,885 compounds

Programmed cell death pathways, including apoptosis, pyroptosis and necroptosis, are regulated by unique sets of host proteins that coordinate a variety of biological outcomes. Pyroptosis is a highly inflammatory form of programmed cell death that occurs most frequently upon infection with intracellular pathogens and is likely to form part of the antimicrobial response. This process promotes the rapid clearance of various bacterial, viral, fungal and protozoan infections by removing intracellular replication niches and enhancing the host's defensive responses. Pyroptosis has been widely studied in inflammatory and infection disease models. Recently, there are growing evidences that pyroptosis also plays an important role in the development of cancer, cardiovascular diseases and Metabolic disorder, etc.

MCE designs a unique collection of 1,885 pyroptosis-related compounds mainly focusing on the key targets in the pyroptosis signaling pathway and can be used in the research of pyroptosis signal pathway and related diseases.

Species:	Human (2)
Tag:	His (2)
Source:	E. coli (2)

Art. -Nr.	Compare	Produktname	Species	Source	Image

HY-P704049

	GSDMD Protein, Human (His) GSDMD; gasdermin D; gasdermin domain containing 1 , GSDMDC1; gasdermin-D; DF5L; FLJ12150; gasdermin domain containing 1; gasdermin domain-containing protein 1; DFNA5L; FKSG10; GSDMDC1	Human	E. coli
	GSDMD Protein, Human (His) is the recombinant human-derived GSDMD protein, expressed by E. coli, with N-6*His tag.

HY-P704049A

	GSDMD Protein, Human (C-His) GSDMD; gasdermin D; gasdermin domain containing 1 , GSDMDC1; gasdermin-D; DF5L; FLJ12150; gasdermin domain containing 1; gasdermin domain-containing protein 1; DFNA5L; FKSG10; GSDMDC1	Human	E. coli
	GSDMD Protein, Human (C-His) is the recombinant human-derived GSDMD protein, expressed by E. coli, with C-6*His tag.

Compare Products


Products	Auf Lager - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / Auf Lager - + In den Warenkorb hinzufügen Angebot einholen

Art. -Nr.	Produktname	Chemical Structure

HY-100573S

Necrosulfonamide-d4
Necrosulfonamide-d₄ is the deuterium labeled Necrosulfonamide (HY-100573). Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.

Necrosulfonamide-d4

Necrosulfonamide-d₄ is the deuterium labeled Necrosulfonamide (HY-100573). Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.

Host:	Rabbit (2)
Reactivity:	Human (2)
Application:	WB (2)
Isotype:	IgG (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (1) Recombinant (1)
Modification:	Unmodified (1)

Art. -Nr.	Compare	Produktname	Application	Reactivity	Image

HY-P83706

	GSDMD Antibody (YA3443) 2 Publications Verification DF 5L; DF5L; DFNA 5L; DFNA5L; FKSG 10; FKSG10; FLJ12150; Gasdermin D; Gasdermin domain containing 1; Gasdermin domain containing protein 1; Gasdermin domain-containing protein 1; Gasdermin-D; GasderminD; GSDMD_HUMAN; GSDMDC 1; GSDMDC1; Gasdermin-D, N-terminal; GSDMD-NT; hGSDMD-NTD; Gasdermin-D, C-terminal; GSDMD-CT; hGSDMD-CTD.	WB	Human
	GSDMD Antibody (YA3443) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GSDMD.

HY-P83706A

	GSDMD Antibody (YA3443)(PBS only) DF 5L; DF5L; DFNA 5L; DFNA5L; FKSG 10; FKSG10; FLJ12150; Gasdermin D; Gasdermin domain containing 1; Gasdermin domain containing protein 1; Gasdermin domain-containing protein 1; Gasdermin-D; GasderminD; GSDMD_HUMAN; GSDMDC 1; GSDMDC1; Gasdermin-D, N-terminal; GSDMD-NT; hGSDMD-NTD; Gasdermin-D, C-terminal; GSDMD-CT; hGSDMD-CTD.	WB	Human
	GSDMD Antibody (YA3443) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GSDMD.

Compare Products


Products	Auf Lager - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / Auf Lager - + In den Warenkorb hinzufügen Angebot einholen

Online-Anfrage

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Anrede			Country or Region *
Name des Antragstellers *			Name der Organisation *
Department *
E-Mail-Addresse *			Produktname *
Art. -Nr.			Requested quantity *
Telefonnummer *
Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.